blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3253750

EP3253750 - NOVEL FLAVONE BASED EGFR INHIBITORS AND PROCESS FOR PREPARATION THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.02.2020
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  08.03.2019
FormerGrant of patent is intended
Status updated on  30.09.2018
FormerRequest for examination was made
Status updated on  10.11.2017
FormerThe international publication has been made
Status updated on  01.09.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Council of Scientific and Industrial Research
Anusandhan Bhawan
Rafi Marg
New Delhi, Maharashtra 110001 / IN
[2017/50]
Inventor(s)01 / KUMAR, Pradeep
National Chemical Laboratory
Dr. Homi Bhabha Road
Maharashtra
411008 Pune / IN
02 / PARIKH, Jignesh Kantilal
National Chemical Laboratory
Dr. Homi Bhabha Road
Maharashtra
Pune 411008 / IN
03 / BEGARI, Eeshwaraiah
National Chemical Laboratory
Dr. Homi Bhabha Road
Maharashtra
Pune 411008 / IN
 [2017/50]
Representative(s)Pfenning, Meinig & Partner mbB
Patent- und Rechtsanwälte
Theresienhöhe 11a
80339 München / DE
[2017/50]
Application number, filing date16718481.103.02.2016
[2017/50]
WO2016IN50037
Priority number, dateIN2015DEL30503.02.2015         Original published format: IN 305DE2015
[2017/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016125186
Date:11.08.2016
Language:EN
[2016/32]
Type: A1 Application with search report 
No.:EP3253750
Date:13.12.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 11.08.2016 takes the place of the publication of the European patent application.
[2017/50]
Type: B1 Patent specification 
No.:EP3253750
Date:10.04.2019
Language:EN
[2019/15]
Search report(s)International search report - published on:EP11.08.2016
ClassificationIPC:C07D417/04, A61K31/427, A61P35/00
[2017/50]
CPC:
C07D417/04 (EP,US); A61P35/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/50]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:NEUARTIGE EGFR-HEMMER AUF FLAVON-BASIS UND VERFAHREN ZU IHRER HERSTELLUNG[2017/50]
English:NOVEL FLAVONE BASED EGFR INHIBITORS AND PROCESS FOR PREPARATION THEREOF[2017/50]
French:NOUVEAUX INHIBITEURS D'EGFR À BASE DE FLAVONE ET PROCÉDÉ DE PRÉPARATION ASSOCIÉ[2017/50]
Entry into regional phase01.09.2017National basic fee paid 
01.09.2017Designation fee(s) paid 
01.09.2017Examination fee paid 
Examination procedure01.09.2017Examination requested  [2017/50]
01.09.2017Date on which the examining division has become responsible
08.03.2018Amendment by applicant (claims and/or description)
01.10.2018Communication of intention to grant the patent
07.02.2019Fee for grant paid
07.02.2019Fee for publishing/printing paid
07.02.2019Receipt of the translation of the claim(s)
Opposition(s)13.01.2020No opposition filed within time limit [2020/12]
Fees paidRenewal fee
27.02.2018Renewal fee patent year 03
27.02.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.02.2016
AL10.04.2019
AT10.04.2019
CY10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
MC10.04.2019
MK10.04.2019
MT10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SI10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
[2022/32]
Former [2022/28]HU03.02.2016
AL10.04.2019
AT10.04.2019
CY10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
MC10.04.2019
MT10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SI10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/50]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
MC10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SI10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/26]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SI10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/17]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/14]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SK10.04.2019
SM10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/12]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SK10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/11]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SK10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/10]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/09]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/04]AL10.04.2019
AT10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/03]AL10.04.2019
AT10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
PT10.09.2019
Former [2019/52]AL10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
PT10.09.2019
Former [2019/51]AL10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
PT10.09.2019
Former [2019/50]AL10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
RS10.04.2019
SE10.04.2019
NO10.07.2019
GR11.07.2019
PT10.09.2019
Former [2019/49]AL10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
NL10.04.2019
SE10.04.2019
NO10.07.2019
PT10.09.2019
Former [2019/48]ES10.04.2019
FI10.04.2019
LT10.04.2019
NL10.04.2019
SE10.04.2019
NO10.07.2019
PT10.09.2019
Former [2019/47]ES10.04.2019
FI10.04.2019
LT10.04.2019
NL10.04.2019
NO10.07.2019
Former [2019/44]NL10.04.2019
Cited inInternational search[A]US2013038940  (SHELESTAK LARRY J [US], et al) [A] 1-11* paragraphs [0002] , [00 6] *;
 [A]WO2013184766  (IRM LLC [US], et al) [A] 1-11 * claims 1, 11 *;
 [A]US2014038940  (XU XIAO [US], et al) [A] 1-11 * claims 1, 11 *
by applicantWO2007026251
    - N SUN ET AL., "A general and facile one-pot process of isothiocyanates from amines under aqueous conditions", BEILSTEIN J ORG CHEM., (2012), vol. 8, pages 61 - 70
    - DT TAYADE ET AL., "Studies in the chemistry of some new 1,2,4-thiadiazolidine by oxidative cyclisation", TERNATIONAL JOURNAL OF CHEMISTRY, (2010), vol. 2, no. 2, pages 40 - 43
    - SV GANDHE ET AL., "Synthesis and Antimicrobial Activity of 3-Amino-5-acyl/alkylimino-1,2,4-thiadiazolines", ASIAN J. CHEM., (2008), vol. 20, no. 1, pages 32 - 36
    - N VUKOVIC ET AL., "Synthesis and antimicrobial evaluation of some novel 2-aminothiazole derivatives of 4-hydroxy-chromene-2-one", ARCH. - PHARM. CHEM. LIFE SCI., (2008), vol. 341, pages 491 - 496
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.